Physician profile
Theodore Sy
NPI 1003865627
$4,342.41
in general payments reported to CMS, 2019-2025
24 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $133 · 2021: $69.21 · 2022: $177 · 2023: $681 · 2024: $1,432 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,381 · Education: $19.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,381.19 |
| Education | $19.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,955.74 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $396.54 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $252.50 | 2019-2025 | |
| Madrigal Pharmaceuticals | $238.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $211.43 | 2023-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $208.90 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $202.16 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $189.41 | 2022-2025 | |
| Pfizer INC. | $95.90 | 2019 | |
| Celltrion USA INC. | $77.13 | 2024-2025 | Zymfentra, Vegzelma |
| Vivus LLC | $76.16 | 2019-2024 | Qsymia |
| Regeneron Healthcare Solutions, INC. | $74.21 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $64.90 | 2023 | Ocaliva |
| Astrazeneca Pharmaceuticals LP | $47.87 | 2019-2020 | |
| Novo Nordisk INC | $45.67 | 2020-2025 | Wegovy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $42.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.27 | 2019 | |
| Braintree Laboratories, INC. | $22.35 | 2024 | Sutab, Suflave |
| Glaxosmithkline, LLC. | $20.69 | 2019 | |
| Redhill Biopharma INC. | $20.65 | 2023 | Talicia |
| Aimmune Therapeutics, INC. | $19.08 | 2024 | |
| Ironwood Pharmaceuticals, INC | $18.07 | 2020 | |
| Shionogi INC | $15.56 | 2019 | |
| Merck Sharp & Dohme LLC | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Sy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.